# A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Source: https://onco.cc/trials/nct00938652/  
OnCo record `nct00938652` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine, Carboplatin and Iniparib in Breast cancer, run by Sanofi, completed.

## Summary

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer is a phase 3 interventional study registered as NCT00938652 by Sanofi, with 519 participants recorded, started 2009-07 and reaching its primary completion in 2011-01. Interventions recorded: gemcitabine/carboplatin, Iniparib. Conditions recorded: Breast Cancer.

Linked to the drug Iniparib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00938652
- Phase: 3
- Setting: A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
- Sponsor: Sanofi
- Enrolled: 519

## Sources

- ClinicalTrials.gov NCT00938652: https://clinicaltrials.gov/study/NCT00938652

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Iniparib](https://onco.cc/drugs/iniparib/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct00938652.json